JUN 03, 2021 8:30 AM PDT

Antibiotics Ineffective Against Lung-Scarring Disease

WRITTEN BY: Annie Lennon

Researchers behind a large trial of antibiotics for chronic lung diseases have found that that the drugs are ineffective in preventing hospitalization or death among those with life-threatening idiopathic pulmonary fibrosis. 

Idiopathic pulmonary fibrosis is a condition in which scar tissue builds up in the lungs over time, gradually preventing them from being able to supply oxygen to the body. The condition typically affects men over the age of 50. After diagnosis, patients survive for an average of 2-5 years. 

So far, doctors are uncertain as to what causes it. Environmental and genetic factors, as well as lung infections, are thought to play a part. However, as studies highlighting the effects of microorganisms on general health have been increasing, the researchers suspected that they may play a role here too. 

Theoretically, they thought, an imbalance of microorganisms in the lungs may have caused the illness. As such, they suspected antimicrobials may have been able to resolve the condition. This came especially after successful trials of antimicrobials in mice. 

For the clinical trial, the researchers recruited 513 patients aged 40 or over with idiopathic pulmonary fibrosis from 35 sites. While half received antimicrobial drugs- either co-trimoxazole or doxycycline, the others received standard care. 

At a median follow-up of 12.7 months, the researchers found that those treated with antimicrobials showed no difference in outcomes to those treated with standard care. Both breathing-related hospitalization and death rates remained the same between the groups. 

"As the largest single study in IPF [idiopathic pulmonary fibrosis] ever conducted, I think we are going to learn a lot as we look at things more closely.” says Imre Noth, one of the study's authors.

“Might our choice of antibiotics have been the right ones? Were there some patients that did better than others? Who should we be targeting for treatment? All things this study will help in the future. I am heartened and hopeful moving forward as this study teaches us a lot for the next one, and each study gets us closer to better treatments and a cure."

While the researchers are disappointed that antimicrobials proved ineffective against the condition, they say that the new research will go some way to prevent unnecessary antibiotic use that could contribute to antibiotic resistance. The trial, the largest for idiopathic pulmonary fibrosis ever conducted, was also helpful in collecting biological samples that may be used in future research. 

 

Sources: EurekAlertJAMA Network

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
OCT 20, 2021
Microbiology
Bacteria From Cats Could Help Treat Infections
OCT 20, 2021
Bacteria From Cats Could Help Treat Infections
Many animals, including humans and cats, harbor huge colonies of microbes, which may live in places like the skin, or th ...
OCT 28, 2021
Immunology
Unlocking a New Target to Treat Gut Inflammation
OCT 28, 2021
Unlocking a New Target to Treat Gut Inflammation
  Immunologists have uncovered a molecular switch in T cells that serves as a prime target for therapeuti ...
NOV 02, 2021
Coronavirus
COVID vaccines have saved 245,000 lives and counting
NOV 02, 2021
COVID vaccines have saved 245,000 lives and counting
What began in December 31, 2019 as a cluster of cases of pneumonia with an unknown etiology, quickly spread throughout t ...
NOV 19, 2021
Health & Medicine
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
NOV 19, 2021
Increase in Cannabis Use Disorder in Prenatal Hospitalizations
A recent study by Columbia University and Weill Cornell Medicine researchers found that cannabis use disorder (CUD) in p ...
NOV 24, 2021
Drug Discovery & Development
A prescription digital therapeutic to treat alcohol use disorders
NOV 24, 2021
A prescription digital therapeutic to treat alcohol use disorders
Can a software application be used treat alcohol use disorders? The medical technology company Pear Therapeutics is ...
DEC 06, 2021
Cancer
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
DEC 06, 2021
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer th ...
Loading Comments...